TSH Biopharm Corporation

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2022, 2021, 2019

In its 2023 reporting, TSH Biopharm Corporation disclosed greenhouse gas emissions of 56.0815 tCO2e/year (Scope 1 & 2). By scope: Scope 1: 0.0009 tCO2e/year; Scope 2: 56.0806 tCO2e/year; Scope 3: 42.8612 + 9.2603 + 28.5743 + 1.8497 + 40.8515 + 0.2993 = 123.7 tCO2e/year (estimated). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
56.0815 tCO2e/year (Scope 1 & 2)
2023
💧
Water Usage
65.7K m3/year
2023
♻️
Waste
1.87 tons/year
2023
⚙️
Energy Use
113.5170 thousand kWh/year
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).0.0009 tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.56.0806 tCO2e/year
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).42.8612 + 9.2603 + 28.5743 + 1.8497 + 40.8515 + 0.2993 = 123.7 tCO2e/year (estimated)

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
202356.0815 tCO2e/year (Scope 1 & 2)
202113.7K kg/year (CO2)
201919.5K kg CO2e/year

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Reduce greenhouse gas emission intensity by 0.5% annually (using 2023 as a baseline)

📅 Medium-term

  • Obtain ISO 14064-1:2018 third-party certification
  • Reduce total energy consumption by 1% in 2029 compared to 2024

🔭 Long-term

  • Achieve carbon neutrality

🌱 ESG Focus Areas

Environmental SustainabilitySocial ResponsibilityCorporate Governance

⚠️ Challenges & Risks +

  • Supply chain disruptions due to uncertain delivery times from European raw material suppliers
  • Poor quality of pharmaceuticals
  • Product stock-outs
  • Major accident at self-operated CDMO facility
  • Regulatory penalties
  • Contractual disputes
  • Information security risks

📋 Report Information

Reporting Period: 2023
Frameworks: GRI Standards, SASB, TCFD, UNGC, ISO 26000
Assurance: Afnor Asia, Ltd.